Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain Mar 11, 2019 3:00 am EDT
Trevena to Report Fourth Quarter and Full Year 2018 Results on March 13, 2019 Mar 4, 2019 7:00 am EST
Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine Jan 28, 2019 7:00 am EST
National Institute on Drug Abuse Presents Data on Trevena’s TRV734 at the 57th Annual Meeting of the American College of Neuropsychopharmacology Dec 13, 2018 4:01 pm EST
Trevena Promotes Robert T. Yoder to Senior Vice President and Chief Business Officer Dec 10, 2018 7:00 am EST
Trevena Reports Third Quarter 2018 Financial Results and Announces Workforce Restructuring Nov 8, 2018 7:00 am EST